Medical technology company Pentax Medical has bought US-based medical device company C2 Therapeutics for an undisclosed amount.

Founded in 2007, C2 Therapeutics is the developer for the CryoBalloon Ablation technology to treat Barrett’s Esophagus and squamous dysplasia.

The device is intended to be used as a cryosurgical tool in the field of general surgery, particularly for endoscopic applications, to include endoscopic ablation of Barrett’s Esophagus with high grade dysplasia.

“The C2 CryoBalloon Ablation System has the potential to improve the lives of millions of people around the world with pre-cancerous lesions of the esophagus.”

The through-the-scope, highly compliant balloon catheter, after being inserted, assumes the shape of the esophageal lumen without creating additional tension on the esophageal wall.

It then allows delivery of targeted dose of cryogen for an immediate ablation of the targeted tissues.

Barrett’s esophagus and squamous dysplasia are characterised with an abnormally changed epithelial cells in the lining of the esophagus to form pre-cursor lesions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These lesions can trigger esophageal cancer in some patients if left unattended.

PENTAX Medical global chief marketing officer David Woods said: “The C2 CryoBalloon Ablation System has the potential to improve the lives of millions of people around the world with pre-cancerous lesions of the esophagus.

“We plan to continue working with thought leaders from around the world to further develop the C2 CryoBalloon Ablation System and commercialise the technology with clinically relevant strategies that meet the therapeutic and economic needs of these targeted patient populations”.

The acquisition is expected to boost Pentax Medical’s therapeutic endoscopy portfolio with the addition of the C2 CryoBalloon Ablation System as well as extend company’s role from being a provider of advanced imaging for diagnostics to providing advanced therapeutic solutions as well.